KK
MLYS icon

KLP Kapitalforvaltning’s Mineralys Therapeutics MLYS Stock Holding History

KLP Kapitalforvaltning’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Buy
12,600
+2,200
+21% +$60.4K ﹤0.01% 1677
2026
Q1 		$282K Buy
10,400
+800
+8% +$23.5K ﹤0.01% 1685
2025
Q4 		$348K Buy
9,600
+2,900
+43% +$116K ﹤0.01% 1589
2025
Q3 		$254K Hold
6,700
– – ﹤0.01% 1721
2025
Q2 		$90.7K Buy
+6,700
New +$97.1K ﹤0.01% 2070

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

KLP Kapitalforvaltning's MLYS Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Mineralys Therapeutics (MLYS) stake by 21% in Q2 2026, buying an estimated $60.4K and bringing the position to 12,600 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

KLP Kapitalforvaltning first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $348K in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • KLP Kapitalforvaltning held 12,600 shares of Mineralys Therapeutics worth $340K as of Q2 2026.
  • KLP Kapitalforvaltning bought 2,200 Mineralys Therapeutics shares in Q2 2026, an estimated $60.4K.
  • Mineralys Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1677 holding.
  • KLP Kapitalforvaltning first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • KLP Kapitalforvaltning's Mineralys Therapeutics position peaked at $348K in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.